scholarly journals The prostacyclin analogue treprostinil in the treatment of pulmonary arterial hypertension

2019 ◽  
Vol 126 (1) ◽  
pp. 32-42 ◽  
Author(s):  
Mia Lindegaard Pedersen ◽  
Marcus Krüger ◽  
Daniela Grimm ◽  
Manfred Infanger ◽  
Markus Wehland
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Prostacyclin Analogue ◽  
Pulmonary Arterial

scholarly journals Transition from Prostacyclin Analogue Infusion to Oral Therapy in Patients with Pulmonary Arterial Hypertension: A 5-Year follow-up

2013 ◽  
Vol 3 (4) ◽  
pp. 880-888 ◽  
Author(s):  
Esteban Escolar ◽  
Andrés M. Pineda ◽  
Barbara Correal ◽  
Tahir Ahmed
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Oral Therapy ◽  
Prostacyclin Analogue ◽  
Pulmonary Arterial

scholarly journals TRANSITION FROM PROSTACYCLIN ANALOGUE INFUSION TO ORAL THERAPY IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: A FIVE YEAR FOLLOW-UP

2013 ◽  
Vol 61 (10) ◽  
pp. E1250
Author(s):  
Andres M. Pineda ◽  
Esteban Escolar ◽  
Barbara Correal ◽  
Tahir Ahmed
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Oral Therapy ◽  
Prostacyclin Analogue ◽  
Pulmonary Arterial

scholarly journals Long-term Survival of Japanese Patients with Pulmonary Arterial Hypertension Treated with Beraprost Sodium, an Oral Prostacyclin Analogue

2014 ◽  
Vol 53 (17) ◽  
pp. 1913-1920 ◽  
Author(s):  
Seiichiro Sakao ◽  
Nobuhiro Tanabe ◽  
Yasunori Kasahara ◽  
Koichiro Tatsumi
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Japanese Patients ◽  
Term Survival ◽  
Long Term Survival ◽  
Prostacyclin Analogue ◽  
Beraprost Sodium ◽  
Pulmonary Arterial

scholarly journals New Oral Drugs for Pulmonary Arterial Hypertension: Macitentan, Riociguat, and Treprostinil

2014 ◽  
Vol 13 (2) ◽  
pp. 68-75 ◽  
Author(s):  
Marco A. Caccamo ◽  
Tim Lahm
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Soluble Guanylate Cyclase ◽  
Clinical Trial Design ◽  
The United States ◽  
World Health ◽  
Oral Drugs ◽  
Prostacyclin Analogue ◽  
Pulmonary Arterial ◽  
Health Organization

In 2013, the US Food and Drug Administration (FDA) approved 3 new oral drugs for the treatment of pulmonary arterial hypertension (PAH; World Health Organization [WHO] Group 1 pulmonary hypertension [PH]). These include the endothelin receptor antagonist macitentan, the soluble guanylate cyclase stimulator riociguat, and the prostacyclin analogue treprostinil. In addition, riociguat was approved for the treatment of patients with inoperable or postsurgery recurrent or persistent chronic thromboembolic PH (CTEPH; WHO Group 4 PH). The approval of these drugs has several important clinical implications: first, in a disease where many of the currently available treatments are complicated by significant side effects and/or complex administration regimens, the availability of new oral drugs clearly represents a valuable addition to the armamentarium. Second, the macitentan study was the first long-term, event-driven trial to be published in the PAH field, making the results more robust and paving the way for improved clinical trial design in the future. Third, riociguat is the first FDA-approved medical treatment regimen for selected CTEPH patients, thus providing a critical treatment option for patients with inoperable or recurrent/persistent CTEPH. Lastly, the approval of oral treprostinil made this drug the first oral prostacyclin analogue to be available in the United States. In this article, the authors will discuss the mechanisms of action of macitentan, riociguat, and oral treprostinil; review the landmark trials that led to the FDA approval of these drugs, and discuss their clinical use.

Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension

2002 ◽  
Vol 165 (6) ◽  
pp. 800-804 ◽  
Author(s):  
GERALD SIMONNEAU ◽  
ROBYN J. BARST ◽  
NAZZARENO GALIE ◽  
ROBERT NAEIJE ◽  
STUART RICH ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Subcutaneous Infusion ◽  
Prostacyclin Analogue ◽  
Continuous Subcutaneous Infusion ◽  
Pulmonary Arterial
Sign in / Sign up

Export Citation Format

Share Document